

**Alaska Medicaid Pharmacy and Therapeutics Committee  
Meeting January 17, 2020**

Frontier Building, 3601 C Street; Room **890/896**

**Agenda**

Public Call in: 1.800.315.6338. Access code **24251#**

1. **Call to Order – Chair** **8:00 am**
2. **Roll Call** **8:05 am**
3. **Public Comment**, including health care professionals

The Department’s methods for class review are to better utilize the time of the P&T Committee. Classes shown in **Red\*** and **Blue\*\*** are classes where new information exists and industry testimony will be taken. Classes shown in **Green** are classes where no significant changes have been noted and no industry testimony will be taken.

*New information includes: \*new drugs or \*\*new indications, new warnings, new head to head clinical evidence.*

4. Class review, discussion & vote.

AK Treatment Class	Drug Class	Status
<b>Respiratory</b>	COPD Agents	<b>RED**</b>
	Glucocorticoids, Inhaled, Single Entity	<b>BLUE**</b>
	Glucocorticoids, Inhaled, Combination	<b>RED**</b>
	Beta Agonists Bronchodilators, Long	GREEN
	Beta Agonists Bronchodilators, Short	<b>BLUE**</b>
<b>Allergy</b>	Epinephrine, Self-Injected	<b>RED**</b>
	Intranasal Rhinitis Agents	GREEN
	Leukotriene Modifiers	GREEN
	Antihistamines, Minimally-Sedating	<b>RED**</b>
<b>Immunological</b>	Cytokine & CAM Antagonists, Non-GI Indications	<b>RED**</b>
	Immunosuppressants, Oral	<b>BLUE**</b>
<b>Dermatological</b>	Antipsoriatics Topical	<b>RED**</b>
	Immunomodulators, Atopic Dermatitis	<b>BLUE**</b>
	Topical Steroids Low Potency	GREEN
	Topical Steroids Medium Potency	GREEN
	Topical Steroids High Potency	GREEN
	Topical Steroids Very High Potency	GREEN
	Acne, Topical	<b>RED**</b>
<b>Ophthalmics</b>	Ophthalmic, Allergic Conjunctivitis	GREEN
	Ophthalmic, Antibiotics	GREEN
	Ophthalmic, Antibiotics-Steroid Combination	GREEN
	Ophthalmic, Anti-inflammatory	<b>BLUE**</b>
	Ophthalmic, Glaucoma Agents	<b>RED**</b>
	Ophthalmic, Immunomodulators	GREEN

7. **Break as needed** – 15 minutes
8. **Review minutes** from **November 2019** meeting
9. **Comments from Committee Members or Chair**
10. **Adjourn**

*Any pharmaceutical manufacturer may submit unsolicited material related to the agenda items by utilizing the Clinical Submission form. Clinical Submissions will be accepted until January 3, 2020 at 4:00pm AK local time. Forms may be found at: [http://dhss.alaska.gov/dhcs/Pages/pdl/download\\_pdl.aspx](http://dhss.alaska.gov/dhcs/Pages/pdl/download_pdl.aspx).*

*Any member of the public, including health care professionals, may submit unsolicited material related to the agenda items by sending an email to [erin.narus@alaska.gov](mailto:erin.narus@alaska.gov) or via mail to 4501 Business Park Blvd, Bldg L, Anchorage, AK 99503. Submissions should be received no later than January 15, 2020 to allow inclusion in the meeting.*

*Next Meeting Date: April 17, 2020*